The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies

被引：38

作者：

Kasprick, Anika ^{[1
]}

Holtsche, Maike M. ^{[2
]}

Rose, Eileen L. ^{[3
]}

Hussain, Sami ^{[3
]}

Schmidt, Enno ^{[1
,2
]}

Petersen, Frank ^{[4
]}

Panicker, Sandip ^{[3
]}

Ludwig, Ralf J. ^{[1
,2
]}

机构：

[1] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany

[2] Univ Lubeck, Dept Dermatol, Lubeck, Germany

[3] True North Therapeut Inc, San Francisco, CA USA

[4] Res Ctr Borstel, Prior Area Asthma & Allergy, Borstel, Germany

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2018年 / 138卷 / 02期

关键词：

DISEASES;

D O I：

10.1016/j.jid.2017.08.030

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：458 / 461

页数：5

共 15 条

[1]

Bernard P, 2009, ARCH DERMATOL, V145, P537, DOI 10.1001/archdermatol.2009.53

[2] Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C [J].

Iwata, Hiroaki ;

Kamaguchi, Mayumi ;

Ujiie, Hideyuki ;

Nishimura, Machiko ;

Izumi, Kentaro ;

Natsuga, Ken ;

Shinkuma, Satoru ;

Nishie, Wataru ;

Shimizu, Hiroshi .

LABORATORY INVESTIGATION, 2016, 96 (12) :1301-1310

[3] Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses [J].

Iwata, Hiroaki ;

Bieber, Katja ;

Hirose, Misa ;

Ludwig, Ralf J. .

CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (18) :2422-2439

[4] Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid [J].

Izumi, Kentaro ;

Nishie, Wataru ;

Mai, Yosuke ;

Wada, Mayumi ;

Natsuga, Ken ;

Ujiie, Hideyuki ;

Iwata, Hiroaki ;

Yamagami, Jun ;

Shimizu, Hiroshi .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (11) :2201-2210

[5] Complement Fixation Test: An Update of an Old Method for Diagnosis of Bullous Pemphigoid [J].

Jankaskova, Jana ;

Horvath, Orsolya N. ;

Varga, Rita ;

Ruzicka, Thomas ;

Sardy, Miklos .

ACTA DERMATO-VENEREOLOGICA, 2016, 96 (02) :197-201

[6] A comparison of oral and topical corticosteroids in patients with bullous pemphigoid [J].

Joly, P ;

Roujeau, JC ;

Benichou, J ;

Picard, C ;

Dreno, B ;

Delaporte, E ;

Vaillant, L ;

D'Incan, M ;

Plantin, P ;

Bedane, C ;

Young, P ;

Bernard, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (05) :321-327

[7] BASEMENT ZONE ANTIBODIES IN BULLOUS PEMPHIGOID [J].

JORDON, RE ;

BEUTNER, EH ;

WITEBSKY, E ;

BLUMENTAL, G ;

HALE, WL ;

LEVER, WF .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1967, 200 (09) :751-+

[8] COMPLEMENT-SYSTEM IN BULLOUS PEMPHIGOID .2. IMMUNOFLUORESCENT EVIDENCE FOR BOTH CLASSICAL AND ALTERNATE-PATHWAY ACTIVATION [J].

JORDON, RE ;

SCHROETER, AL ;

GOOD, RA ;

DAY, NK .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1975, 3 (03) :307-314

[9] Human IgG1 Monoclonal Antibody against Human Collagen 17 Noncollagenous 16A Domain Induces Blisters via Complement Activation in Experimental Bullous Pemphigoid Model [J].

Li, Qiang ;

Ujiie, Hideyuki ;

Shibaki, Akihiko ;

Wang, Gang ;

Moriuchi, Reine ;

Qiao, Hong-jiang ;

Morioka, Hiroshi ;

Shinkuma, Satoru ;

Natsuga, Ken ;

Long, Heather A. ;

Nishie, Wataru ;

Shimizu, Hiroshi .

JOURNAL OF IMMUNOLOGY, 2010, 185 (12) :7746-7755

[10] Emerging treatments for pemphigoid diseases [J].

Ludwig, Ralf J. ;

Kalies, Kathrin ;

Koehl, Joerg ;

Zillikens, Detlef ;

Schmidt, Enno .

TRENDS IN MOLECULAR MEDICINE, 2013, 19 (08) :501-512

← 1 2 →